Biotechnology Assets S.A. Total Assets
Biotechnology Assets S.A. total assets. Based on the latest financial reports, Biotechnology Assets S.A. (BST) holds total assets worth €13.46 Million EUR (≈ $15.73 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Biotechnology Assets S.A. for the company's overall valuation and market capitalisation.
Total Assets of Biotechnology Assets S.A. (2010–2024)
Total assets of Biotechnology Assets S.A. from 2010 to 2024. This chart illustrates how Biotechnology Assets S.A.'s total assets have evolved over time, based on quarterly financial data. See BST live share price for real-time trading data and today's change.
Biotechnology Assets S.A. - Asset Composition Analysis
Biotechnology Assets S.A. Total Assets Breakdown (December 2024)
Biotechnology Assets S.A. total assets breakdown as of December 2024. Biotechnology Assets S.A.'s total assets of €13.46 Million consist of 25.0% current assets and 75.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 1.0% |
| Accounts Receivable | €3.43 Million | 23.2% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.18 Million | 28.3% |
| Goodwill | €1.46 Million | 9.9% |
Asset Composition Trend (2010–2024)
This chart illustrates how Biotechnology Assets S.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Biotechnology Assets S.A. short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biotechnology Assets S.A.'s current assets represent 25.0% of total assets in 2024, an increase from 24.4% in 2010.
- Cash Position: Cash and equivalents constituted 1.0% of total assets in 2024, up from 0.4% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 37.0% of total assets, an increase from 27.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 28.3% of total assets.
Biotechnology Assets S.A. Competitors by Total Assets
Key competitors of Biotechnology Assets S.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Biotechnology Assets S.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.02 | 0.85 | 0.79 |
| Quick Ratio | 1.02 | 0.85 | 0.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €50.66K | €-512.67K | €-6.67 Million |
Biotechnology Assets S.A. - Advanced Valuation Insights
This section examines the relationship between Biotechnology Assets S.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.11 |
| Latest Market Cap to Assets Ratio | 0.91 |
| Asset Growth Rate (YoY) | -11.0% |
| Total Assets | €14.78 Million |
| Market Capitalization | $13.52 Million USD |
Valuation Analysis
Near Book Valuation: The market values Biotechnology Assets S.A.'s assets close to their book value (0.91x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Biotechnology Assets S.A.'s assets decreased by 11.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biotechnology Assets S.A. (2010–2024)
The table below shows the annual total assets of Biotechnology Assets S.A. from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €14.78 Million ≈ $17.28 Million |
-10.98% |
| 2023-12-31 | €16.61 Million ≈ $19.42 Million |
-10.11% |
| 2022-12-31 | €18.47 Million ≈ $21.60 Million |
-7.05% |
| 2021-12-31 | €19.88 Million ≈ $23.24 Million |
-1.66% |
| 2020-12-31 | €20.21 Million ≈ $23.63 Million |
-78.19% |
| 2019-12-31 | €92.67 Million ≈ $108.34 Million |
+16.95% |
| 2018-12-31 | €79.24 Million ≈ $92.64 Million |
+350.63% |
| 2017-12-31 | €17.58 Million ≈ $20.56 Million |
+10.09% |
| 2016-12-31 | €15.97 Million ≈ $18.67 Million |
+7.93% |
| 2015-12-31 | €14.80 Million ≈ $17.30 Million |
+0.79% |
| 2014-12-31 | €14.68 Million ≈ $17.17 Million |
+58.79% |
| 2013-12-31 | €9.25 Million ≈ $10.81 Million |
+21.46% |
| 2012-12-31 | €7.61 Million ≈ $8.90 Million |
+4.37% |
| 2011-12-31 | €7.29 Million ≈ $8.53 Million |
+45.03% |
| 2010-12-31 | €5.03 Million ≈ $5.88 Million |
-- |
About Biotechnology Assets S.A.
Biotechnology Assets, S.A. develops and markets biotechnological assets for applications in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industries in Spain and internationally. It offers SPLITTERA, a protein engineering tool that allows the conjugation of proteins through the formation of new peptide bonds; universal switchable split-chimeric antigen receptor (CAR); VA… Read more